Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asim Amin

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
Transitional cell carcinoma recurrence presenting as isolated transverse sinus thrombosisAsim Amin
Translational Lung Cancer Research|December 3, 2015
Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicitiesJeryl Villadolid, Asim Amin
Frontiers in Immunology|January 29, 2019
The Evolving Landscape of Immunotherapy-Based Combinations for Frontline Treatment of Advanced Renal Cell CarcinomaAsim Amin, Hans Hammers
Journal of Kidney Cancer and VHL|March 23, 2017
Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?Asim Amin, Richard L White
Oncology (Williston Park, N.Y.)|August 28, 2013
High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies?Asim Amin, Richard L White
Seminars in Oncology|May 15, 2016
Skin manifestations associated with kidney cancerAsim Amin, Earle F Burgess
Surgical Oncology Clinics of North America|June 7, 2011
Cancer immunotherapyRichard L White, Asim Amin
Cancer Management and Research|January 30, 2015
Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal diseaseLudimila Cavalcante, Asim Amin, Jose Lutzky
Current Medical Research and Opinion|January 4, 2018
First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapyNizar Tannir, Hans Hammers, Asim Amin
Breast Cancer Research and Treatment|May 8, 2014
Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in PakistanMuhammad U Rashid, Noor Muhammad, Saima Faisal, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
Transitional cell carcinoma recurrence presenting as isolated transverse sinus thrombosisAsim Amin
Translational Lung Cancer Research|December 3, 2015
Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicitiesJeryl Villadolid, Asim Amin
Frontiers in Immunology|January 29, 2019
The Evolving Landscape of Immunotherapy-Based Combinations for Frontline Treatment of Advanced Renal Cell CarcinomaAsim Amin, Hans Hammers
Journal of Kidney Cancer and VHL|March 23, 2017
Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?Asim Amin, Richard L White
Oncology (Williston Park, N.Y.)|August 28, 2013
High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies?Asim Amin, Richard L White
Seminars in Oncology|May 15, 2016
Skin manifestations associated with kidney cancerAsim Amin, Earle F Burgess
Surgical Oncology Clinics of North America|June 7, 2011
Cancer immunotherapyRichard L White, Asim Amin
Cancer Management and Research|January 30, 2015
Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal diseaseLudimila Cavalcante, Asim Amin, Jose Lutzky
Current Medical Research and Opinion|January 4, 2018
First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapyNizar Tannir, Hans Hammers, Asim Amin
Breast Cancer Research and Treatment|May 8, 2014
Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in PakistanMuhammad U Rashid, Noor Muhammad, Saima Faisal, et al.
Pageof 6